Clinical trial
Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma
NCT00283543 · Kentuckiana Cancer Institute, Other · Unknown status
Key facts
| NCT number | NCT00283543 |
|---|---|
| Title | Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma |
| Official title | A Phase II Study of Radiation With Concomitant and Then Sequential Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Who Have Undergone Surgery With Gliadel Wafer Insertion |
| Lead sponsor | Kentuckiana Cancer Institute, Other |
| Collaborators | Eisai Inc. Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Newly Diagnosed Supratentorial Malignant Glioma |
| Intervention type | Drug, Procedure |
| Interventions | Gliadel Wafer, Temozolomide, Limited field radiation |
| Enrollment | 40 |
| Start date | Sep 1, 2002 |
| Completion | Apr 1, 2008 |
| First posted | Jan 30, 2006 |
| Last update posted | Oct 31, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: